Invesco Ltd. Boosts Stock Position in Glaukos Co. (NYSE:GKOS)

Invesco Ltd. increased its position in Glaukos Co. (NYSE:GKOS - Free Report) by 4.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,458,635 shares of the medical instruments supplier's stock after purchasing an additional 68,310 shares during the quarter. Invesco Ltd. owned approximately 2.65% of Glaukos worth $218,708,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. William Blair Investment Management LLC bought a new stake in shares of Glaukos in the fourth quarter valued at about $121,390,000. Alliancebernstein L.P. raised its stake in Glaukos by 1,235.4% in the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock worth $122,374,000 after buying an additional 755,035 shares in the last quarter. Norges Bank purchased a new stake in Glaukos during the fourth quarter worth $84,490,000. Raymond James Financial Inc. bought a new stake in Glaukos during the 4th quarter valued at $16,910,000. Finally, Vanguard Group Inc. increased its holdings in shares of Glaukos by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier's stock valued at $895,887,000 after acquiring an additional 101,838 shares during the period. 99.04% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have issued reports on GKOS shares. Truist Financial cut their price target on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Wells Fargo & Company boosted their price target on Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Mizuho decreased their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday. Piper Sandler dropped their target price on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday. Finally, Stifel Nicolaus upped their target price on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and a consensus price target of $156.17.

Glaukos Price Performance

Shares of Glaukos stock traded up $2.02 on Thursday, hitting $90.82. The company's stock had a trading volume of 188,507 shares, compared to its average volume of 635,560. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 1 year low of $77.91 and a 1 year high of $163.71. The firm has a fifty day moving average price of $110.40 and a 200-day moving average price of $131.88. The company has a market capitalization of $5.14 billion, a price-to-earnings ratio of -31.59 and a beta of 0.88.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, sell-side analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.